ID: ALA1086621

Max Phase: Preclinical

Molecular Formula: C32H38F2N2O4

Molecular Weight: 552.66

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc(C(=O)N2CCN(CCCCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc(OC)c1OC

Standard InChI:  InChI=1S/C32H38F2N2O4/c1-38-29-21-25(22-30(39-2)31(29)40-3)32(37)36-19-17-35(18-20-36)16-6-4-5-7-28(23-8-12-26(33)13-9-23)24-10-14-27(34)15-11-24/h8-15,21-22,28H,4-7,16-20H2,1-3H3

Standard InChI Key:  PVRUBEUPMQSJRW-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 552.66

Molecular Weight (Monoisotopic): 552.2800

AlogP: 6.14

#Rotatable Bonds: 12

Polar Surface Area: 51.24

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 2

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 7.48

CX LogP: 6.14

CX LogD: 5.80

Aromatic Rings: 3

Heavy Atoms: 40

QED Weighted: 0.25

Np Likeness Score: -0.72

References

1. Zamponi GW, Feng ZP, Zhang L, Pajouhesh H, Ding Y, Belardetti F, Pajouhesh H, Dolphin D, Mitscher LA, Snutch TP..  (2009)  Scaffold-based design and synthesis of potent N-type calcium channel blockers.,  19  (22): [PMID:19815411] [10.1016/j.bmcl.2009.09.008]

Source

Source(1):

• Scientific Literature